Identification of some infants at immediate risk of dying unexpectedly and justifying intensive study

Lancet (London, England)
|August 18, 1979
PubMed

Insights

Unexpected infant deaths can be predicted. Infants with two or more symptoms have a 1 in 50 chance of death within 9 days, allowing for early intervention.

Area of Science:

  • Pediatrics
  • Public Health
  • Infant Mortality

Background:

  • Infant mortality remains a significant public health concern.
  • Unexpected infant deaths often follow identifiable illness symptoms.
  • Early identification of at-risk infants is crucial for prevention.

Purpose of the Study:

  • To evaluate the risk of unexpected infant death associated with pre-existing illness symptoms.
  • To develop a predictive model for identifying high-risk infants.

Main Methods:

  • Utilized survey data on infant symptoms and discriminant analysis.
  • Developed a risk score based on data collected at birth and at 1 month.
  • Analyzed the association between symptom clusters and unexpected infant death.

Main Results:

  • Infants with two or more symptoms, identified as high-risk by the discriminant score, have a 1 in 50 chance of unexpected death within 9 days.
  • The predictive system identifies approximately 50% of sudden infant deaths (cot deaths).

Conclusions:

  • A discriminant score-based system can identify infants at high risk for unexpected death.
  • This predictive model offers a foundation for prospective physiological studies.
  • Early identification of at-risk infants can potentially reduce mortality rates.

Related Concept Videos

CRISPR01:59

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...